Compare BAH & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAH | RDY |
|---|---|---|
| Founded | 1914 | 1984 |
| Country | United States | India |
| Employees | 31500 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.9B |
| IPO Year | 2010 | 2001 |
| Metric | BAH | RDY |
|---|---|---|
| Price | $70.75 | $12.31 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 15 | 5 |
| Target Price | ★ $85.23 | $13.31 |
| AVG Volume (30 Days) | 1.4M | ★ 2.5M |
| Earning Date | 10-23-2026 | 10-23-2026 |
| Dividend Yield | ★ 3.40% | 0.51% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $11,217,000,000.00 | N/A |
| Revenue This Year | $1.70 | $4.73 |
| Revenue Next Year | $4.39 | $11.63 |
| P/E Ratio | $42.93 | ★ $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $59.50 | $11.36 |
| 52 Week High | $109.10 | $15.67 |
| Indicator | BAH | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 54.62 |
| Support Level | $69.99 | $12.09 |
| Resistance Level | $80.95 | $12.48 |
| Average True Range (ATR) | 2.06 | 0.21 |
| MACD | -0.81 | 0.07 |
| Stochastic Oscillator | 26.57 | 64.87 |
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.